# Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke

> **NCT04097652** · PHASE1 · UNKNOWN · sponsor: **Meridigen Biotech Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **BIOLOGICAL:** UMC119-06

## Key facts

- **NCT ID:** NCT04097652
- **Lead sponsor:** Meridigen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04097652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04097652, "Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04097652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*